265
Views
12
CrossRef citations to date
0
Altmetric
Research Article

Ocular Effects of Exposure to Industrial Chemicals: Clinical Management and Proteomic Approaches to Damage Assessment

, , &
Pages 203-225 | Published online: 10 Oct 2008

REFERENCES

  • Belke JC. Chemical accidents risks in US industry—a preliminary analysis of accident risk data from US hazardous chemical facilities. EPA Stockholm Report. Washington, DC: US Environmental Protection Agency; 2000.
  • Bertazzi PA. Long-term effects of chemical disasters. Lessons and results from seveso. Sci Total Environ 1991; 106(1–2):5–20.
  • Bertazzi PA. Industrial disasters and epidemiology. A review of recent experiences. Scand J Work Environ Health 1989; 15(2): 85–100.
  • de Souza Porto MF, de Freitas CM. Major chemical accidents in industrializing countries: the socio-political amplification of risk. Risk Anal 1996; 16(1): 19–29.
  • Regulations ECoF. 2004.
  • Lindell MK, Perry RW. Community innovation in hazardous materials management: progress in implementing SARA Title III in the United States. Superfund Amendments and Reauthorization Act. J Hazard Mater 2001; 88(2–3):169–194.
  • Schierow L-J. Chemical Plant Security. Report for Congress. Washington, DC: Congressional Research Service; 2003 January 23, 2003.
  • Homeland security: voluntary initiatives are under way at chemical facilities, but the extent of security preparedness is unknown. Washington, DC: United States General Accounting Office; 2003 March 2003.
  • Elliott MR, Wang Y, Lowe RA, Kleindorfer PR. Environmental justice: frequency and severity of US chemical industry accidents and the socioeconomic status of surrounding communities. J Epidemiol Community Health 2004; 58(1): 24–30.
  • Kleindorfer PR, Belke JC, Elliott MR, Lee K, Lowe RA, Feldman HI. Accident epidemiology and the U.S. chemical industry: accident history and worst-case data from RMP*Info. Risk Anal 2003; 23(5): 865–881.
  • Hazardous substances emergency events surveillance. Annual Report. Atlanta, Georgia: Agency for Toxic Substances and Disease Registry, US Department of Health and Human Services; 2001.
  • Anhydrous ammonia theft. Washington, DC: US Environmental Protection Agency; 2000 March 2000. Report No.: 5104.
  • Drug data summary: Executive office of the President, US Office of National Drug Control Policy; 2003.
  • Acute public health consequences of methamphetamine laboratories—16 states. MMWR Morb Mortal Wkly Rep 2005; 54(14):356–359.
  • Houghton BK. Gearing Up and Getting There: Improving Local Response to Chemical Terrorism; 2004.
  • Shea DA, Gottron F. Small-Scale Terrorist Attacks Using Chemical and Biological Agents: An Assessment Framework and Preliminary Comparisons; Washington, D.C.: Federation of American Scientists; 2004.
  • Prine C. Chemical sites still vulnerable. Pittsburgh Tribune-Review. 2003 November 16, 2003.
  • Hom GG. Chemical, biological, and radiological weapons: implications for optometry and public health. Optometry 2003; 74(2): 81–98.
  • Kales SN, Christiani DC. Acute chemical emergencies. N Engl J Med 2004; 350(8): 800–808.
  • Transportation Research Board NAoS. Cooperative Research for Hazardous Materials Transportation: Defining the Need, Converging on Solutions. Special Report No 283. 2005.
  • Murphy T. Terrorism danger looms along railroad tracks Protection measures are few for tank cars laden with chemicals. Portland Tribune. 2003 Oct 3, 2003.
  • Fleischauer E. Will terrorism ride into town on a train? The Decatur Daily News. 2004.
  • Riley J. Terrorism and Rail Security; Santa Monica: RAND Corporation; 2004 2004.
  • Cohn D, Fernandez M, Fuller N, Harris HR, Rein L, Stockwell J, et al. Metro in brief: Emergency hazmat ban near mall backed. Washington Post. November 6, 2004; Sect. B03.
  • Career guide to industries. Chemical Manufacturing, Except Pharmaceutical and Medicine Manufacturing: U.S. Department of Labor Bureau of Labor Statistics; 2004.
  • Koscheyev VS, Leon GR, Greaves IA. Lessons learned and unsolved public health problems after large-scale disasters. Prehospital Disaster Med 1997; 12(2): 120–131.
  • Srivastava AK, Gupta BN. Oculotoxins: effects, implications, and importance in occupational health. Am J Ind Med 1989; 16(6): 723–726.
  • Keeney AH, Kuhn, HS, MacDonald, R. Industrial and Traumatic Ophthalmology; St. Louis: Mosby, 1964.
  • Sanford AP, Herndon, DN. Chemical burns. In: Herndon DN, ed. Total Burn Care. New York: Saunders; 2002:475–480.
  • Hall HI HG, Price-Green PA, Dhara VR, Kaye WE. Risk Factors for hazardous substances releases that result in injuries and evacuations: data from 9 states. Am J Public Health 1996; 86(6): 855–857.
  • Kim T, Khosla-Gupta, BA. Chemical and thermal injuries to the ocular surface. In: Holland EJ, Mannis MJ, eds. Ocular Surface Diseases: Medical and Surgical Management. New York: Springer-Verlag; 2002:100–112.
  • McCulley JP. Corneal trauma: Chemical agents. In: Smolin G, Thoft RA, eds. The Cornea: Scientific Foundations and Clinical Practice. Boston: Little, Brown and Company; 1994:614–633.
  • Wagoner MD. Chemical injuries of the eye: current concepts in pathophysiology and therapy. Surv Ophthalmol 1997; 41(4): 275–313.
  • Li W, Yuan X, Nordgren G, Dalen H, Dubowchik GM, Firestone RA, et al. Induction of cell death by the lysosomotropic detergent MSDH. FEBS Lett 2000; 470(1): 35–39.
  • Ralph RA. Chemical injuries of the eye. In: Tasman W, Jaeger, EA., eds. Duane's Clinical Ophthalmology. Philadelphia: Lippincott; 1998.
  • Kuckelkorn R, Kottek A, Schrage N, Reim M. Poor prognosis of severe chemical and thermal eye burns: the need for adequate emergency care and primary prevention. Int Arch Occup Environ Health 1995; 67(4): 281–284.
  • Millea TP, Kucan JO, Smoot EC, 3rd. Anhydrous ammonia injuries. J Burn Care Rehabil 1989; 10(5): 448–453.
  • Amoore JE, Hautala E. Odor as an aid to chemical safety: Odor thresholds compared with threshold limit values and volatilities for 214 industrial chemicals in air and water dilution. J Appl Toxicol 1983; 3(6): 272–290.
  • Managing hazardous materials incidents, vol. III—medical management guidelines for acute chemical exposures. Atlanta: US Department of Health and Human Services; 1992.
  • Horton DK, Berkowitz Z, Kaye WE. The public health consequences from acute chlorine releases, 1993–2000. J Occup Environ Med 2002; 44(10): 906–913.
  • Weisskopf MG, Drew JM, Hanrahan LP, Anderson HA, Haugh GS. Hazardous ammonia releases: public health consequences and risk factors for evacuation and injury, United States, 1993–1998. J Occup Environ Med 2003; 45(2): 197–204.
  • Weisskopf MG, Drew JM, Hanrahan LP, Anderson HA. Hazardous ammonia releases in Wisconsin: trends and risk factors for evacuation and injury. Wmj 2000; 99(8):30–33, 46.
  • Anhydrous ammonia thefts and releases associated with illicit methamphetamine production—16 states. MMWR Morb Mortal Wkly Rep 2005; 54(14):359–361.
  • Irvine GD, Chin, L. The environmental impact and adverse health effects of the clandestine manufacture of methamphetamine. NIDA Res Monogr 1991; 115: 33–46.
  • Charukamnoetkanok P, Wagoner, M.D. Facial and Ocular injuries associated with methamphetamine production accidents. Am J Ophtalmol 2004; 138(5): 875–876.
  • Lee JH, Farley CL, Brodrick CD, Blomquist PH. Anhydrous ammonia eye injuries associated with illicit methamphetamine production. Ann Emerg Med 2003; 41(1):157.
  • Horton DK, Berkowitz Z, Kaye WE. Secondary contamination of ED personnel from hazardous materials events, 1995–2001. Am J Emerg Med 2003; 21(3): 199–204.
  • Morse J, Eck, D. Ammonia spill evacuates 300—thief seeking meth ingredient left valve open, officials said. The Cincinnati Enquirer. 2004 Feb 19.
  • Wagner SP. Report says Minot derailment preventable.: The Forum, Minot part 5; 2003.
  • In the matter of the derailment of the Canadian Pacific Railroad, freight train 292–16, near Minot. Minot, North Dakota: National Transportation Safety Board; 2002.
  • Bismuth C, Borron SW, Baud FJ, Barriot P. Chemical weapons: documented use and compounds on the horizon. Toxicol Lett 2004; 149(1–3):11–18.
  • Yanoff M, Fine, BS. Ocular Pathology: A Text and Atlas, 3rd ed.; Philadelphia: Lippincott; 1989.
  • Managing Hazardous Materials Incidents, vol. II—Hospital Emergency Departments: A Planning Guide for the Management of Contaminated Patients; Atlanta: US Department of Health and Human Services; 1992.
  • Alberta Chlorine Spill, Alberton, Montana: phase I Study Report; Atlanta: US Department of Health and Human Services; 1998.
  • Evaluation of residual respiratory and other health effects from a chlorine release near Alberton, Montana: phase II study report. Atlanta: US Department of Health and Human Services; 2001.
  • Dhara VR, Dhara R. The Union Carbide disaster in Bhopal: a review of health effects. Arch Environ Health 2002; 57(5): 391–404.
  • Rhode D. 20 years later, Bhopal gas-leak victims to get their due. San Diego Union-Tribune July 20, 2004 July 20, 2004 [cited; A3]. Available from: http://www.signonsandiego.com/uniontrib/20040720/news_1n20bhopal.html.
  • McPhate M. City of poison: Bhopal residents limp through toxic sludge 20 years after Union Carbide chemical leak. San Francisco Chronicle. December 5, 2004; Sect. B-1.
  • Salmon AG, Kerr Muir M, Andersson N. Acute toxicity of methyl isocyanate: a preliminary study of the dose response for eye and other effects. Br J Ind Med 1985; 42(12): 795–798.
  • Dhara VR, Dhara R, Acquilla SD, Cullinan P. Personal exposure and long-term health effects in survivors of the union carbide disaster at Bhopal. Environ Health Perspect 2002; 110(5): 487–500.
  • Andersson N, Muir MK, Mehra V. Bhopal eye. Lancet 1984; 2(8417–8418):1481.
  • Raizada JK, Dwivedi PC. Chronic ocular lesions in Bhopal gas tragedy. Indian J Ophthalmol 1987; 35(5–6):453–454.
  • Naik SR, Acharya VN, Bhalerao RA, Kowli SS, Nazareth H, Mahashur AA, et al. Medical survey of methyl isocyanate gas affected population of Bhopal. Part I. General medical observations 15 weeks following exposure. J Postgrad Med 1986; 32(4): 175–184.
  • Wagoner MD, Kenyon, K. R. Chemical injuries: emergency intervention. In: Kuhn F, Pieramici DJ, eds. Ocular Trauma: Principles and Practice. New York: Thieme; 2002:77–83.
  • Wagoner MD, Kenyon KR. Chemical injuries: Clinical course and management. In: Kuhn F, Pieramici DJ, eds. Ocular Trauma: Principles and Practice. New York: Thieme; 2002:335–349.
  • Kenyon KR, Chaves HV. Morphology and pathologic response of corneal and conjunctival disease. In: Smolin G, Thoft RA, eds. The Cornea: Scientific Foundations and Clinical Practice. Boston: Little, Brown and Company; 1994:69–111.
  • Matelis KH, Congdon N. Glaucoma. In: Kuhn F, Pieramici DJ, eds. Ocular Trauma: Principles and Practice. New York: Thieme; 2002:169–179.
  • Sotozono C, He J, Tei M, Honma Y, Kinoshita S. Effect of metalloproteinase inhibitor on corneal cytokine expression after alkali injury. Invest Ophthalmol Vis Sci 1999; 40(10): 2430–2434.
  • Woessner JF, Jr. The family of matrix metalloproteinases. Ann N Y Acad Sci 1994; 732: 11–21.
  • Reim M, Bahrke C, Kuckelkorn R, Kuwert T. Investigation of enzyme activities in severe burns of the anterior eye segment. Graefes Arch Clin Exp Ophthalmol 1993; 231(5): 308–312.
  • Moses MA. The regulation of neovascularization of matrix metalloproteinases and their inhibitors. Stem Cells 1997; 15(3): 180–189.
  • Lehrer MS, Sun TT, Lavker RM. Strategies of epithelial repair: Modulation of stem cell and transit amplifying cell proliferation. J Cell Sci 1998; 111(Pt 19):2867–2875.
  • Schrage NF, Langefeld S, Zschocke J, Kuckelkorn R, Redbrake C, Reim M. Eye burns: An emergency and continuing problem. Burns 2000; 26(8): 689–699.
  • Lee RC, Astumian RD. The physicochemical basis for thermal and non-thermal ‘burn’ injuries. Burns 1996; 22(7): 509–519.
  • Kuyven CR, Gomes DR, Serra MC, Macieira L, Pitanguy I. Major burn injury caused by helium vapour. Burns 2003; 29(2): 179–181.
  • George A, Bang RL, Lari AR, Gang RK, Kanjoor JR. Liquid ammonia injury. Burns 2000; 26(4): 409–413.
  • Kerstein MD, Schaffzin DM, Hughes WB, Hensell DO. Acute management of exposure to liquid ammonia. Mil Med 2001; 166(10): 913–914.
  • Frazer DG, Armstrong MF, Archer DB. Compression keratopathy. Am J Ophthalmol 1986; 102(2): 208–210.
  • Vidan A, Luria S, Eisenkraft A, Hourvitz A. Ocular injuries following sulfur mustard exposure: Clinical characteristics and treatment. Isr Med Assoc J 2002; 4(7): 577–578.
  • Hur GH, Kim YB, Choi DS, Kim JH, Shin S. Apoptosis as a mechanism of 2-chloroethylethyl sulfide-induced cytotoxicity. Chem Biol Interact 1998; 110(1–2):57–70.
  • Dacre JC, Goldman M. Toxicology and pharmacology of the chemical warfare agent sulfur mustard. Pharmacol Rev 1996; 48(2): 289–326.
  • Safarinejad MR, Moosavi SA, Montazeri B. Ocular injuries caused by mustard gas: Diagnosis, treatment, and medical defense. Mil Med 2001; 166(1): 67–70.
  • Yanoff MF BS. Ocular Pathology; 5th ed.; Philadelphia: Mosby, 2002.
  • Lardot C, Dubois V, Lison D. Sulfur mustard upregulates the expression of interleukin-8 in cultured human keratinocytes. Toxical Lett 1999; 110(1–2):29–33.
  • Atkins KB, Lodhi IJ, Hurley LL, Hinshaw DB. N-acetylcysteine and endothelial cell injury by sulfur mustard. J Appl Toxicol 2000; 20(Suppl 1):S125–S128.
  • Kadivar H, Adams SC. Treatment of chemical and biological warfare injuries: Insights derived from the 1984 Iraqi attack on Majnoon Island. Mil Med 1991; 156(4): 171–177.
  • Lee RJ, Yolton RL, Yolton DP, Schnider C, Janin ML. Personal defense sprays: Effects and management of exposure. J Am Optom Assoc 1996; 67(9): 548–560.
  • Yih JP. CS gas injury to the eye. Bmj 1995; 311(7000):276.
  • Willoughby CF, Ilango B, Hughes A. CS gas ocular injury. Eye 1998; 12(Pt 1):164.
  • Kuckelkorn R, Schrage N, Keller G, Redbrake C. Emergency treatment of chemical and thermal eye burns. Acta Ophthalmol Scand 2002; 80(1): 4–10.
  • Kompa S, Redbrake C, Hilgers C, Wustermeyer H, Schrage N, Remky A. Effect of different irrigating solution on aqueous humor pH changes, intraocular pressure, and histological findings after induced alkali burns. Acta Ophthalmol Scand 2005; 83(4): 467–470.
  • Herr RD, White GL, Jr., Bernhisel K, Mamalis N, Swanson E. Clinical comparison of ocular irrigation fluids following chemical injury. Am J Emerg Med 1991; 9(3): 228–231.
  • Schrage NF, Kompa S, Ballman B, Langefield S. Relationship of eye burns with calcifications of the cornea? Graefes Arch Clin Exp Ophthalmol 2005; 243(8):228–231.
  • Choy CK, Benzie IF, Cho P. Is ascorbate in human tears from corneal leakage of from lacrimal secretion? Clin Exp Optom 2004; 87(1):24–27.
  • Burns FR, Stack MS, Gray RD, Paterson CA. Inhibition of purified collagenase from alkali-burned rabbit corneas. Invest Ophthalmol Vis Sci 1989; 30(7): 1569–1575.
  • Solomon A, Rosenblatt M, Li DQ, Liu Z, Monroy D, Ji Z, et al. Doxycycline inhibition of interleukin-1 in the corneal epithelium. Invest Ophthalmol Vis Sci 2000; 41(9): 2544–2557.
  • Li de Q, Shang TY, Kim HS, Solomon A, Lokeshwar BL, Pflugfelder SC. Regulated expression of collagenases MMP-1, -8, and -13 and stromelysins MMP-3, -10, and -11 by human corneal epithelial cells. Invest Ophthalmol Vis Sci 2003; 44(7): 2928–2936.
  • Li DQ, Lokeshwar BL, Solomon A, Monroy D, Ji Z, Pflugfelder SC. Regulation of MMP-9 production by human corneal epithelial cells. Exp Eye Res 2001; 73(4): 449–459.
  • Lapp CA, Lohse JE, Lewis JB, Dickinson DP, Billman M, Hanes PJ, et al. The effects of progesterone on matrix metalloproteinases in cultured human gingival fibroblasts. J Periodontol 2003; 74(3): 277–288.
  • Li Q, Fukuda K, Lu Y, Nakamura Y, Chikama T, Kumagai N, et al. Enhancement by neutrophils of collagen degradation by corneal fibroblasts. J Leukoc Biol 2003; 74(3): 412–419.
  • He J, Bazan NG, Bazan HE. Alkali-induced corneal stromal melting prevention by a novel platelet-activating factor receptor antagonist. Arch Ophthalmol 2006; 124(1): 70–78.
  • Shimazaki J, Shimmura S, Tsubota K. Donor source affects the outcome of ocular surface reconstruction in chemical or thermal burns of the cornea. Ophthalmology 2004; 111(1): 38–44.
  • Nishida K, Yamato M, Hayashida Y, Watanabe K, Yamamoto K, Adachi E, et al. Corneal reconstruction with tissue-engineered cell sheets composed of autologous oral mucosal epithelium. N Engl J Med 2004; 351(12): 1187–1196.
  • Ma Y, Xu Y, Xiao Z, Yang W, Zhang C, Song E, et al. Reconstruction of chemically burned rat corneal surface by bone marrow-derived human mesenchymal stem cells. Stem Cells 2006; 24(2): 315–321.
  • Holland EJ, Schwartz GS. The evolution and classification of ocular surface transplantation. In: Holland EJaM MJ, ed. Ocular Surface Diseases: Medical and Surgical Management. New York: Springer-Verlag; 2002:149–157.
  • Daya S, Watson A, Sharpe JR, Giledi O, Rowe A, Martin R, et al. Outcomes and DNA analysis of ex vivo expanded stem cell allograft for ocular surface reconstruction. Ophthalmology 2005; 112(3): 470–477.
  • Ivekovic R, Tedeschi-Reiner E, Novak-Laus K, Andrijevic-Derk B, Cima I, Mandic Z. Limbal graft and/or amniotic membrane transplantation in the treatment of ocular burns. Ophthalmologica 2005; 219(5): 297–302.
  • Tamhane A, Vajpayee RB, Biswas NR, Pandey RM, Sharma N, Titital JS, et al. Evaluation of amniotic membrane transplantation as an adjunct to medical therapy as compared with medical therapy alone in acute ocular burns. Ophthalmology 2005; 112(11): 1963–1969.
  • Arora R, Mehta D, Jain V. Amniotic membrane transplantation in acute chemical burns. Eye 2005; 19(3): 273–278.
  • Gomes JA, dos Santos MS, Cunha MC, Mascaro VL, Barros Jde N, de Sousa LB. Amniotic membrane transplantation for partial and total limbal stem cell deficiency secondary to chemical burn. Ophthalmology 2003; 110(3): 466–473.
  • Stoiber J, Muss WH, Pohla-Gubo G, Ruckhofer J, Grabner G. Histopathology of human corneas after amniotic membrane and limbal stem cell transplantation for severe chemical burn. Cornea 2002; 21(5): 482–489.
  • Jain S, Rastogi A. Evaluation of the outcome of amniotic membrane transplantation for ocular surface reconstruction in symblepharon. Eye 2004.
  • Achauer BM, Adair SR. Acute and reconstructive management of the burned eyelid. Clin Plast Surg 2000; 27(1):87–96, vi.
  • Beare JD. Eye injuries from assault with chemicals. Br J Ophthalmol 1990; 74(9): 514–518.
  • Young RC, Ho WS, Ying SY, Burd A. Chemical assaults in Hong Kong: A 10-year review. Burns 2002; 28(7): 651–653.
  • Mandrekas AD, Zambacos GJ, Anastasopoulos A. Treatment of bilateral severe eyelid burns with skin grafts: An odyssey. Burns 2002; 28(1): 80–86.
  • Rosania GR. Supertargeted chemistry: Identifying relationships between molecular structures and their sub-cellular distribution. Curr Top Med Chem 2003; 3(6): 659–685.
  • Warnock DE, Fahy E, Taylor SW. Identification of protein associations in organelles, using mass spectrometry-based proteomics. Mass Spectrom Rev 2004; 23(4): 259–280.
  • Huang S. Genomics, complexity and drug discovery: Insights from Boolean network models of cellular regulation. Pharmacogenomics 2001; 2(3): 203–222.
  • Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, et al. The sequence of the human genome. Science 2001; 291(5507): 1304–1351.
  • Vukmirovic OG, Tilghman SM. Exploring genome space. Nature 2000; 405(6788): 820–822.
  • Pognan F. Genomics, proteomics and metabonomics in toxicology: Hopefully not ‘fashionomics’. Pharmacogenomics 2004; 5(7): 879–893.
  • Pandey A, Mann M. Proteomics to study genes and genomes. Nature 2000; 405(6788): 837–846.
  • Figeys D, McBroom LD, Moran MF. Mass spectrometry for the study of protein-protein interactions. Methods 2001; 24(3): 230–239.
  • Farmer TB, Caprioli RM. Determination of protein-protein interactions by matrix-assisted laser desorption/ionization mass spectrometry. J Mass Spectrom 1998; 33(8): 697–704.
  • Godovac-Zimmermann J, Brown LR. Perspectives for mass spectrometry and functional proteomics. Mass Spectrom Rev 2001; 20(1): 1–57.
  • Stasyk T, Huber LA. Zooming in: Fractionation strategies in proteomics. Proteomics 2004:3704–3716.
  • Mayr M, Mayr U, Chung YL, Yin X, Griffiths JR, Xu Q. Vascular proteomics: Linking proteomic and metabolomic changes. Proteomics 2004:3751–3761.
  • Sorensen M, Autrup H, Moller P, Hertel O, Jensen SS, Vinzents P, et al. Linking exposure to environmental pollutants with biological effects. Mutat Res 2003; 544(2–3):255–271.
  • Gibson BW. Exploiting proteomics in the discovery of drugs that target mitochondrial oxidative damage. Sci Aging Knowledge Environ 2004; 2004(11):pe12.
  • Merrick BA. The human proteome organization (HUPO) and environmental health. EHP Toxicogenomics 2003; 111(1T): 1–5.
  • Kumar GK, Klein JB. Analysis of expression and posttranslational modification of proteins during hypoxia. J Appl Physiol 2004; 96(3):1178–1186; discussion 0–2.
  • Chaurand P, Schwartz SA, Caprioli RM. Assessing protein patterns in disease using imaging mass spectrometry. J Proteome Res 2004; 3(2): 245–252.
  • Gimeno MJ, Bellon JM, Bujan J. [Ocular changes associated with connective tissue disorders: Role of the elastic and collagen components]. Arch Soc Esp Oftalmol 2001; 76(8): 459–469.
  • Waters MD, Olden K, Tennant RW. Toxicogenomic approach for assessing toxicant-related disease. Mutat Res 2003; 544(2–3):415–424.
  • Joo WA, Kang MJ, Son WK, Lee HJ, Lee DY, Lee E, et al. Monitoring protein expression by proteomics: Human plasma exposed to benzene. Proteomics 2003; 3(12): 2402–2411.
  • Joo WA, Sul D, Lee DY, Lee E, Kim CW. Proteomic analysis of plasma proteins of workers exposed to benzene. Mutat Res 2004; 558(1–2):35–44.
  • Karring H, Thogersen IB, Klintworth GK, Moller-Pederson T, Enghild JJ. A dataset of human cornea proteins identified by peptide mass fingerprinting and tandem mass spectrometry. Mol Cell Proteomics 2005; 4(9): 1406–1408.
  • Karring H, Thogersen IB, Klintworth GK, Enghild JJ, Moller-Pederson T. Proteomic analysis of the soluble fraction from human corneal fibroblasts with reference to ocular transparency. Mol Cell Proteomics 2004; 3(7): 660–674.
  • Seow T, Korke R, Liang RC, Ong SE, Ou K, Wong K, et al. Proteomic investigation of metabolic shift in mammalian cell culture. Biotechnol Prog 2001; 17(6): 1137–1144.
  • Risa O, Saether O, Midelfart A, Krane J, Cejkova J. Analysis of immediate changes of water-soluble metabolites in alkali-burned rabbit cornea, aqueous humor and lens by high-resolution 1H-NMR spectroscopy. Graefes Arch Clin Exp Ophthalmol 2002; 240(1): 49–55.
  • Stramer B, Cook JR, Fini ME, Taylor A, Obin M. Induction of the ubiquitin-proteasome pathway during the keratocyte transition to the repair fibroblast phenotype. Invest Ophthalmol Vis Sci 2001; 42(8): 1698–1706.
  • Fang Y, Choi D, Searles RP, Mathers WD. A time course microarray study of gene expression in the mouse lacrimal gland after acute corneal trauma. Invest Ophthalmol Vis Sci 2005; 46(2): 461–469.
  • Li N, Wang N, Zheng J, Liu XM, Lever OW, Erickson PM, et al. Characterization of human tear proteome using multiple proteomic analysis techniques. J Proteome Res 2005; 4(6): 2052–2061.
  • Wilson S, Liang Q, Kim WJ. Lacrimal gland HGF, KGF, and EGF mRNA levels increase after corneal epithelial wounding. Invest Ophthalmol Vis Sci 1999; 40(10): 2185–2190.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.